Killer peptide helps eliminate resistant cancer cells
Scientists have identified a Par-4 amino-terminal fragment that is released by diverse therapy-sensitive cancer cells…
Scientists have identified a Par-4 amino-terminal fragment (PAF) that is released by diverse therapy-sensitive cancer cells following therapy-induced cleavage of the tumour suppressor Par-4 protein. PAF caused death in cancer cells resistant to therapy and inhibited metastatic tumour growth, in the study, published in Cancer Research.
The PAF entered only cancer cells, not normal cells, keeping healthy tissue intact. The findings indicate that this naturally generated PAF could potentially be harnessed to target neighbouring or distant cancer cells to overcome metastasis and therapy resistance in tumours.
“This new information could positively impact how physicians plan their treatments, so as to use the sensitive cells in the tumour to release this peptide to help eliminate the resistant cells,” said Vivek Rangnekar, principal investigator and Alfred Cohen Chair in Oncology Research with the University of Kentucky College of Medicine’s Department of Radiation Medicine. “We are developing PAF against therapy-resistant tumour metastasis for which no other treatment options are available.”
Webinar: Integrated drug discovery panel – your questions answered!
During this peer panel discussion, team members from Charles River will discuss their views and strategies on Drug Discovery.
Tumour relapse is a common problem following cancer treatment, because primary tumour cells often contain therapy-resistance cancer cells that continue to proliferate after the therapy-sensitive cells have been eliminated.